RGNX
Price
$9.40
Change
+$0.04 (+0.43%)
Updated
Sep 26, 02:44 PM (EDT)
Capitalization
472.81M
40 days until earnings call
ZBIO
Price
$19.80
Change
+$1.18 (+6.34%)
Updated
Sep 26, 01:32 PM (EDT)
Capitalization
784.09M
46 days until earnings call
Interact to see
Advertisement

RGNX vs ZBIO

Header iconRGNX vs ZBIO Comparison
Open Charts RGNX vs ZBIOBanner chart's image
REGENXBIO
Price$9.40
Change+$0.04 (+0.43%)
Volume$100
Capitalization472.81M
Zenas Biopharma
Price$19.80
Change+$1.18 (+6.34%)
Volume$100
Capitalization784.09M
RGNX vs ZBIO Comparison Chart in %
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. ZBIO commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Buy and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (RGNX: $9.36 vs. ZBIO: $18.62)
Brand notoriety: RGNX and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 95% vs. ZBIO: 117%
Market capitalization -- RGNX: $472.81M vs. ZBIO: $784.09M
RGNX [@Biotechnology] is valued at $472.81M. ZBIO’s [@Biotechnology] market capitalization is $784.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both RGNX and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 5 TA indicator(s) are bullish while ZBIO’s TA Score has 3 bullish TA indicator(s).

  • RGNX’s TA Score: 5 bullish, 4 bearish.
  • ZBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ZBIO.

Price Growth

RGNX (@Biotechnology) experienced а 0.00% price change this week, while ZBIO (@Biotechnology) price change was -4.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.35%. For the same industry, the average monthly price growth was +8.66%, and the average quarterly price growth was +50.94%.

Reported Earning Dates

RGNX is expected to report earnings on Nov 05, 2025.

ZBIO is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+3.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($784M) has a higher market cap than RGNX($473M). ZBIO YTD gains are higher at: 127.350 vs. RGNX (21.087). RGNX has higher annual earnings (EBITDA): -129.93M vs. ZBIO (-189M). RGNX has more cash in the bank: 323M vs. ZBIO (273M). ZBIO has less debt than RGNX: ZBIO (1.01M) vs RGNX (77.7M). RGNX has higher revenues than ZBIO: RGNX (156M) vs ZBIO (15M).
RGNXZBIORGNX / ZBIO
Capitalization473M784M60%
EBITDA-129.93M-189M69%
Gain YTD21.087127.35017%
P/E RatioN/AN/A-
Revenue156M15M1,040%
Total Cash323M273M118%
Total Debt77.7M1.01M7,708%
FUNDAMENTALS RATINGS
RGNX vs ZBIO: Fundamental Ratings
RGNX
ZBIO
OUTLOOK RATING
1..100
6720
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5036
P/E GROWTH RATING
1..100
20100
SEASONALITY SCORE
1..100
n/a46

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZBIO's Valuation (41) in the null industry is in the same range as RGNX (69) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to RGNX’s over the last 12 months.

ZBIO's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that RGNX’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (36) in the null industry is in the same range as RGNX (50) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for ZBIO (100) in the null industry. This means that RGNX’s stock grew significantly faster than ZBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXZBIO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 24 days ago
77%
Bullish Trend 3 days ago
90%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMXAX16.60N/A
N/A
Nationwide Mid Cap Market Idx A
PMDDX19.31N/A
N/A
Principal Small-MidCap Dividend Inc C
ANDIX16.41N/A
N/A
AQR International Defensive Style I
MCGAX10.74N/A
N/A
Transamerica Mid Cap Growth A
PSLGX148.20N/A
N/A
Putnam Sustainable Leaders R6

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with PYXS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
-8.19%
PYXS - ZBIO
42%
Loosely correlated
-5.07%
CRNX - ZBIO
42%
Loosely correlated
+2.02%
NUVL - ZBIO
42%
Loosely correlated
-2.54%
REPL - ZBIO
41%
Loosely correlated
-2.64%
RGNX - ZBIO
40%
Loosely correlated
-1.89%
More